Comparing Imbruvica vs Zanubrutinib
| Imbruvica (ibrutinib) | Zanubrutinib |
|
|---|
| Imbruvica (ibrutinib) | Zanubrutinib |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Imbruvica is an oral tablet that may be taken once daily to treat certain types of cancers in adults or to treat chronic Graft Versus Host disease in adults and children older than 1 year. It works... View more |
Prescription only
Prescribed for Waldenström Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma. Zanubrutinib may also be used for purposes not listed in... View more |
Related suggestions Popular comparisons
|
|||||||
| More about Imbruvica (ibrutinib) | More about Zanubrutinib | ||||||||
| Ratings & Reviews | |||||||||
|
Imbruvica has an average rating of 6.6 out of 10 from a total of 69 ratings on Drugs.com. 59% of reviewers reported a positive effect, while 30% reported a negative effect. |
Zanubrutinib has an average rating of 8.8 out of 10 from a total of 61 ratings on Drugs.com. 82% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
View all Imbruvica side effects |
View all Zanubrutinib side effects |
||||||||
| Drug Class | |||||||||
| Generic Availability | |||||||||
|
N/A |
|||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||
View all Imbruvica prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | |||||||||
|
N/A |
||||||||
| Brand Names | |||||||||
|
N/A |
Brukinsa | ||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
|
6 hours |
4 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | |||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
| Drug Interactions | |||||||||
|
A total of 506 drugs are known to interact with Imbruvica:
|
A total of 527 drugs are known to interact with Zanubrutinib:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||
|
|
||||||||
| Disease Interactions | |||||||||
| First Approval Date | |||||||||
|
November 13, 2013 |
November 14, 2019 |
||||||||
| WADA Class View classifications | |||||||||
|
N/A |
N/A |
||||||||
| More Information | |||||||||
| Patient Resources | |||||||||
| Professional Resources | |||||||||
| Related Treatment Guide | |||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Jakafi
Jakafi is used to treat certain types of myelofibrosis or polycythemia vera in adults, and certain ...
Deltasone
Deltasone is used for acute lymphocytic leukemia, adrenocortical insufficiency, allergic reactions ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Rayos
Rayos (prednisone, delayed-release) is used to treat rheumatoid arthritis, polymyalgia rheumatica ...
Rasuvo
Rasuvo is used for polyarticular juvenile idiopathic arthritis, psoriasis, rheumatoid arthritis
Trexall
Trexall is used for acute lymphoblastic leukemia, acute lymphocytic leukemia, breast cancer ...
Otrexup
Otrexup is used for polyarticular juvenile idiopathic arthritis, psoriasis, rheumatoid arthritis
Sterapred
Sterapred is used for acute lymphocytic leukemia, adrenocortical insufficiency, allergic reactions ...
Ruxolitinib
Ruxolitinib (oral) is used to treat certain types of myelofibrosis (MF), polycythemia vera (PV) ...
Methotrexate
Methotrexate is used to treat certain types of cancer of the breast, skin, head and neck, or lung ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.